Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239745 | 0.81 | THRB (0.32) | KDM4EGAAL3MBTL1 | |
| SCHEMBL29241167 | 0.69 | CYP2C9 (0.33) | CYP2C9CYP2C19 | |
| SCHEMBL1119711 | 0.66 | CYP2C9 (0.31) | CYP2C9CYP2C19 | |
| SCHEMBL28527648 | 0.66 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL28525796 | 0.66 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL5909667 | 0.65 | CYP1A2 (0.59) | KDM4EALDH1A1GAALMNACYP1A2 | |
| SCHEMBL79594 | 0.65 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL28498943 | 0.65 | KMT2A (0.32) | KDM4EALDH1A1GAALMNACYP1A2 | |
| SCHEMBL2079080 | 0.64 | MMP2 (0.30) | — | |
| SCHEMBL27497690 | 0.64 | KDM4E (0.45) | KDM4EALDH1A1GAALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | KDM4E 1988/4885ALDH1A1 724/4885GAA 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.